{
    "nctId": "NCT01233947",
    "briefTitle": "Study of AFP464 +/- Faslodex in ER + Breast Cancer",
    "officialTitle": "A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Clinical Benefit Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* proven breast cancer, ER+ status; progression on an aromatase inhibitor; measurable disease or evaluable disease with serum CA27.29\\>=50 U/mL; adequate bone marrow, liver and renal function; DLco grade 0 or 1.\n\nExclusion Criteria:\n\n* HER2 positive, thoracic radiotherapy or symptomatic pulmonary disease, brain metastases,",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}